Abstract: Hybrid cell line for production of monoclonal antibody to an antigen found on normal human monocytes and granulocytes. The hybrid is formed by fusing splenocytes from immunized BALB/cJ mice with P3X63Ag8U1 myeloma cells. Diagnostic and therapeutic uses of the monoclonal antibody are also disclosed.

Abstract: Hybrid cell line for production of monoclonal antibody to an antigen found on normal human monocytes and granulocytes. The hybrid is formed by fusing splenocytes from immunized BALB/cJ mice with P3X63Ag8Ul myeloma cells. Diagnostic and therapeutic uses of the monoclonal antibody are also disclosed.

Abstract: Hybrid cell line for production of monoclonal antibody to an antigen found on essentially all normal human T cells and on approximately 95% of normal human thymocytes. The hybrid is formed by fusing splenocytes from immunized CAF.sub.1 mice with P3X63Ag8U1 myeloma cells. Diagnostic and therapeutic uses of the monoclonal antibody are also disclosed.

Abstract: Novel [[4-[4-(4-phenyl-1-piperazinyl)phenoxymethyl]-1,3-dioxolan-2-yl]methyl]-1H -imidazoles and 1H-1,2,4-triazoles, having anti-microbial activity, compositions containing the same, and methods of inhibiting and/or eliminating the development of fungi and bacteria in warm-blooded animals suffering from diseases caused by these fungi and/or bacteria.

Abstract: Hybrid cell line for production of monoclonal antibody to an antigen found on approximately 95% of normal human thymocytes. The hybrid is formed by fusing splenocytes from immunized CAF.sub.1 mice with P3X63Ag8U1 myeloma cells. Diagnostic and therapeutic uses of the monoclonal antibody are also disclosed.

Abstract: The present invention is related with .alpha.-aryl-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3H)-yl)benzeneaceton itriles which are effective in destructing or preventing the growth of Protozoa in subjects suffering from such Protozoa.

Abstract: A method of detecting and localizing nucleic acids on polyamide supports which comprises contacting said supports with a suspension of colloidal metal particles whereupon the metal particles bind to the polyamide support and form a colored background against which the location where nucleic acids are present become visible as lighter spots. The method enables the mere qualitative localization of the nucleic acids and the quantitative determination thereof following art-known procedures.

Abstract: A method for detecting and/or determining an agglomerate formed by the reaction between a specific binding agent and the corresponding acceptor substance according to the general methodology of blot overlay assays by using colloidal metal particles labelled components which may be visualized as a coloured signal at the surface of the blotting medium characteristric for the colloidal metal particles used or quantitatively determined following art-known spectrophotometric procedures such as densitometry.

Abstract: A method for controlling weeds preferably in the crops of useful plants by using a 1-methyl-1H-imidazole-5-carboxylic acid derivative; herbicidal compositions containing the same; 1-methyl-1H-imidazole-5-carboxylic acid derivatives.

Abstract: Novel 5,6-dihydro-2-(substituted phenyl)-1,2,4-triazine-3,5(2H,4H)-diones which are effective in destroying or preventing the growth of Protozoa in subjects suffering from such Protozoa.

Abstract: Novel N-aryl-piperazinealkanamides, having particular substituents attached to one of the carbon atoms of the piperazine ring, which compounds are useful to protect hearts from myocardial injury caused by ischaemia, anoxia or hypoxia.

Abstract: This invention relates to .gamma.-cyclodextrin ethers and mixed ethers wherein the ether substituents are C.sub.1 -C.sub.6 alkyl, hydroxy C.sub.1 -C.sub.6 alkyl, carboxy C.sub.1 -C.sub.6 alkyl or (C.sub.1 -C.sub.6 alkyloxycarbonyl) C.sub.1 -C.sub.6 alkyl; provided that hydroxypropyl is not a sole substituent.

Abstract: Novel N-(bicyclic heterocyclyl)-4-piperidinamines having antihistaminic and serotonin-antagonistic properties which are useful in the treatment of allergic diseases.

Abstract: A method of visualizing individual submicroscopic metal particles by subjecting said particles to bright field or epi-polarization microscopy and enhancing the contrast of the image so obtained by electronic means.

Abstract: A method for treating allergy by administration of the peptide thymopentin.

Abstract: Novel [[[(3-pyridinyl)methylen]amino]oxy]alkanoic acids and esters, compositions containing the same, and methods of treating clinical conditions related with the production of thromboxane A.sub.2, prostacyclin and/or prostaglandins D.sub.2, E.sub.2 and F.sub.2.alpha..

Abstract: Hybrid cell line for production of monoclonal antibody to an antigen found on essentially all normal human T cells and on approximately 95% of normal human thymocytes. The hybrid is formed by fusing splenocytes from immunized CAF.sub.1 mice with P3X63Ag8U1 myeloma cells. Diagnostic and therapeutic uses of the monoclonal antibody are also disclosed.

Abstract: Substituted [[4-[4-(4-phenyl-1-piperazinyl)phenoxymethyl]-1,3 dioxolan-2-yl]methyl]-1H-imidazoles and 1H-1,2,4-triazoles having antimicrobial properties and being particularly useful in the treatment of vaginal candidosis.

Abstract: A stable mutant human T cell line is disclosed which secretes a high titer suppressor inducer factor. This suppressor inducer factor in turn induces production of a T cell suppressor factor which suppressed mitogen-induced T cell proliferation at high dilution. Also disclosed is a general method for mutating lymphoblastoid cell lines to yield mutants secreting enhanced levels of lymphokines.

Abstract: An amino-protected L-aspartic acid, such as t-butyloxycarbonyl-beta-benzyl-L-aspartic acid, is prepared by first forming the amino-protected compound in the presence of a tertiary amine base having a pK.sub.a value of about 9 to about 12, water, and a water-immiscible polar organic solvent so as to produce a non-aqueous solution containing a salt form of amino-blocked-beta-benzyl-L-aspartic acid. The thus produced non-aqueous solution is then isolated, or next acidified and treated further to ultimately recover therefrom the amino-protected L-aspartic acid in crystalline form.